StockProfiler.US: Stock Profiler.US: Stock Watch: VSYM, SLP, ENZ, ISCO

View Systems, Inc. (OTCBB: VSYM); Simulations Plus, Inc. (NASDAQ: SLP); Enzo Biochem, Inc. (NYSE: ENZ); International Stem Cell Corporation (OTCBB: ISCO)

StockProfiler.US is Introducing Leading Microcap Companies! We welcome Investors to sign up and subscribe to our FREE Newsletter at www.stockprofiler.us. Please follow our thread on www.twitter.com at StockProfilerUS

-------------------------------------------

View Systems, Inc. closed at $0.017 Monday, trading 380,445 shares.

Company News- October 13, 2009: View Systems Continues to Promote Retail Sales On FiberXpress.com

View Systems, Inc. (OTCBB: VSYM), a security and teledata solutions provider, announced earlier today that the company continues to promote FiberXpress, Inc., a web-based business that specializes in online sales of fiber and copper networking equipment and connectivity products. View acquired FiberXpress, Inc. in July.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About View Systems, Inc.

View Systems, Inc. manufactures and installs weapons detection identification systems, video management platforms and teledata communication networks targeted towards correctional facilities, schools, courthouses, government agencies, event and sports venues, and commercial businesses. More information can be found on the website at www.viewsystems.com.

-------------------------------------------

Simulations Plus, Inc. closed at $1.53 Monday, trading 14,100 shares.

Company News- October 13, 2009: Simulations Plus Releases ClassPharmer(TM) Version 4.7

Earlier today Simulations Plus, Inc. (NASDAQ: SLP) announced the release of ClassPharmer 4.7, the latest version of its state-of-the-art software used by pharmaceutical research scientists for analysis of chemical libraries and design of new molecular structures.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. The Company's Words+ subsidiary, which provides assistive technology for persons with disabilities, as well as two retail products, Abbreviate! and FutureLab(TM), comprise the remainder of the business. Simulations Plus is headquartered in Southern California and trades on the NASDAQ under the symbol "SLP." For more information, visit our Web site at www.simulations-plus.com.

-------------------------------------------

Enzo Biochem, Inc. closed at $7.26 Monday, trading 79,602 shares.

Company News- October 13, 2009: Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Year-End 2009 Results for October 15, 2009, at 8:30 AM E.T.

Earlier today the following was announced:

Enzo Biochem, Inc. (NYSE: ENZ), will hold a conference call to discuss its fiscal 2009 fourth quarter results on Thursday, October 15, 2009, at 8:30 AM ET.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Enzo Biochem

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

-------------------------------------------

International Stem Cell Corporation closed at $0.55 Monday, trading 330,445 shares.

Company News- October 13, 2009: International Stem Cell Corporation, Through Its Subsidiary Lifeline Cell Technology, Announces the Launch and Sale of New Products into the Human Cell Research Market

International Stem Cell Corporation (OTCBB: ISCO) (www.internationalstemcell.com), announced earlier today that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human "parthenogenetic" stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com.

-------------------------------------------

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division includes but is not limited to: www.stockprofiler.us; www.associatesfortune.com; www.fastmoneytalk.com; www.markettelegraph.com; www.thewallstreetleader.com; and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.

Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes

CONTACT: StockProfiler.US e-mail: info@stockprofiler.us WWW: http://www.stockprofiler.us

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: advisor, art, bank, biology, biotechnology, broker, business, california, commercial, community, conference, copper, dealer, e-mail, engineering, euro, finance, government, health, investment, investment opinion, manufacturer, market, media, nasdaq, networking, nyse, online, pharmaceuticals, products, research, retail, retail sales, revenue, sales, securities, security, small cap, software, sports, technology, track, video, weapons, web